title: The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.
abstract: OBJECTIVE Salsalate is a nonacetylated salicylate that lowers glucose levels in people with type 2 diabetes (T2D). Here we examined whether salsalate also lowered serum-protein-bound levels of early and advanced glycation end products (AGEs) that have been implicated in diabetic vascular complications. RESEARCH DESIGN AND METHODS Participants were from the Targeting Inflammation Using Salsalate for Type 2 Diabetes (TINSAL-T2D) study, which examined the impact of salsalate treatment on hemoglobin A1c (HbA1c) and a wide variety of other parameters. One hundred eighteen participants received salsalate, 3.5 g/day for 48 weeks, and 109 received placebo. Early glycation product levels (HbA1c and fructoselysine [measured as furosine]) and AGE levels (glyoxal and methylglyoxal hydroimidazolones [G-(1)H, MG-(1)H], carboxymethyllysine [CML], carboxyethyllysine [CEL], pentosidine) were measured in patient serum samples. RESULTS Forty-eight weeks of salsalate treatment lowered levels of HbA1c and serum furosine (P < 0.001) and CML compared with placebo. The AGEs CEL and G-(1)H and MG-(1)H levels were unchanged, whereas pentosidine levels increased more than twofold (P < 0.001). Among salsalate users, increases in adiponectin levels were associated with lower HbA1c levels during follow-up (P < 0.001). Changes in renal and inflammation factor levels were not associated with changes in levels of early or late glycation factors. Pentosidine level changes were unrelated to changes in levels of renal function, inflammation, or cytokines. CONCLUSIONS Salsalate therapy was associated with a reduction in early but not late glycation end products. There was a paradoxical increase in serum pentosidine levels suggestive of an increase in oxidative stress or decreased clearance of pentosidine precursor.
authors.affiliation: Corresponding author: Joshua I. Barzilay, joshua.barzilay@kp.org.
authors.forename: Joshua I
authors.initials: JI
authors.lastname: Barzilay
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Jablonski
authors.forename: Vivian
authors.initials: V
authors.lastname: Fonseca
authors.forename: Steven E
authors.initials: SE
authors.lastname: Shoelson
authors.forename: Allison B
authors.initials: AB
authors.lastname: Goldfine
authors.forename: Christopher
authors.initials: C
authors.lastname: Strauch
authors.forename: Vincent M
authors.initials: VM
authors.lastname: Monnier
mesh_terms: D052242:Adiponectin / Q000097:blood; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000517:prevention & control; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives / Q000097:blood; D008297:Male; D008875:Middle Aged; D011765:Pyruvaldehyde / Q000097:blood; D012459:Salicylates / Q000627:therapeutic use*
chemical_list: D052242:Adiponectin; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001120:Arginine; D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D008239:Lysine; D011765:Pyruvaldehyde; D012459:Salicylates; C018948:furosine; C033186:fructosyl-lysine; C048496:N(6)-carboxymethyllysine; C062187:pentosidine; C014182:salicylsalicylic acid